John F. Paolini - 16 Mar 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 16 Mar 2023
Net transactions value: -$17,798
Form type: 4
Filing time: 20 Mar 2023, 17:20:05 UTC
Previous filing: 09 Nov 2022
Next filing: 03 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+1,725	+4.7%		38,060	16 Mar 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$5,810	-507	-1.3%	$11.46	37,553	16 Mar 2023	Direct
transaction	KNSA	Class A Common Share	Options Exercise		+3,671	+9.8%		41,224	20 Mar 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$11,987	-1,078	-2.6%	$11.12	40,146	20 Mar 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-1,725	-33%	$0.000000	3,450	16 Mar 2023	Class A Common Share	1,725		Direct	F1, F2
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-3,671	-100%	$0.000000^*	0	20 Mar 2023	Class A Common Share	3,671		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.
F3	The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.